Medical&Pharma Research

07/13/2022

Asian, Black, Hispanic Patients Have Higher Pulse Oximetry Readings

Learn more -> https://www.empr.com/home/news/asian-black-hispanic-patients-have-higher-pulse-oximetry-readings/

06/15/2022

New Cancer Drugs Approved Faster in US Than Europe

Learn more -> https://www.empr.com/home/news/new-cancer-drugs-approved-faster-in-us-than-europe/

06/01/2022

Monkeypox Not the Next Pandemic, WHO Expert Says

Learn more ->

In current outbreak, vast majority of cases are being seen in gay and bisexual men

05/19/2022

Guideline Updated for Management of Spontaneous ICH

Learn more -> https://www.empr.com/home/news/guideline-updated-for-management-of-spontaneous-ich/

04/28/2022

Annual Costs Estimated for Wart Treatment in the US for 2015 to 2017

Learn more ->

Per-patient costs for evaluation and management estimated at $288.28 for cutaneous warts and $431.47 for anogenital warts in 2019

04/21/2022

Hidden Drugs Found in Supplements Promoted for Musculoskeletal Conditions

Learn more ->

Laboratory analyses revealed certain Artri and Ortiga products contain undeclared drug ingredients.

04/12/2022

Intra-Articular Injection of Triamcinolone Beneficial in Hip Osteoarthritis

Learn more -> https://www.empr.com/home/news/intra-articular-injection-of-triamcinolone-beneficial-in-hip-osteoarthritis/

03/31/2022

Health Care Reform under the Biden Administration

The Biden administration has made important incremental progress in expanding access to affordable health insurance. But its struggles to enact a broader reform agenda reflect the daunting political constraints that limit U.S. health policy.

Learn more -> https://www.nejm.org/doi/full/10.1056/NEJMp2202813?query=featured_home

03/29/2022

Elamipretide Gets Orphan Drug Status for Friedreich Ataxia

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/elamipretide-gets-orphan-drug-status-for-friedreich-ataxia/

03/24/2022

Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia

Learn more -> https://www.nejm.org/doi/full/10.1056/NEJMoa2114897?query=featured_home

03/22/2022

A comprehensive framework for early-onset colorectal cancer research

Learn more -> https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00588-X/fulltext

03/17/2022

Trial of a Cereblon Modulator in SLE

In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not significant at lower doses. Urinary tract and respiratory tract infections and neutropenia occurred.

Learn more -> https://www.nejm.org/doi/full/10.1056/NEJMoa2106535?query=featured_home